Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial

on behalf of the, VX14-809-109 investigator group, VX14-809-109 investigator group

Research output: Contribution to journal › Article › peer-review

128 Scopus citations

Fingerprint Dive into the research topics of 'Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences